Search

Your search keyword '"Collée, Margriet"' showing total 114 results

Search Constraints

Start Over You searched for: Author "Collée, Margriet" Remove constraint Author: "Collée, Margriet"
114 results on '"Collée, Margriet"'

Search Results

1. Evaluation of the recently established Dutch nationwide Archipelago of Ovarian Cancer Research biobank

2. A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer

3. Association analysis identifies 65 new breast cancer risk loci

4. Reproductive decision-making in the context of hereditary cancer: the effects of an online decision aid on informed decision-making

5. RAD51B in Familial Breast Cancer.

6. Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers

7. The development of an online decision aid to support persons having a genetic predisposition to cancer and their partners during reproductive decision-making: a usability and pilot study

8. Ovarian stimulation for IVF and risk of primary breast cancer in BRCA1/2 mutation carriers

9. Establishment of the Dutch Nationwide, Interdisciplinary Infrastructure and Biobank for Fundamental and Translational Ovarian Cancer Research:Archipelago of Ovarian Cancer Research (AOCR)

10. Establishment of the Dutch Nationwide, Interdisciplinary Infrastructure and Biobank for Fundamental and Translational Ovarian Cancer Research: Archipelago of Ovarian Cancer Research

11. Data from Variation in Mutation Spectrum Partly Explains Regional Differences in the Breast Cancer Risk of Female BRCA Mutation Carriers in the Netherlands

12. Supplementary Tables 1 through 5 from Variation in Mutation Spectrum Partly Explains Regional Differences in the Breast Cancer Risk of Female BRCA Mutation Carriers in the Netherlands

13. The BRCA1 c. 5096G>A p.Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA consortium

14. Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers:A nationwide cohort study

15. Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study

16. Establishment of the Dutch nationwide, interdisciplinary infrastructure and biobank for fundamental and translational ovarian cancer research: Archipelago of Ovarian Cancer Research (AOCR).

17. Effect of a health literacy training program for surgical oncologists and specialized nurses on disparities in referral to breast cancer genetic testing

18. Effect of a health literacy training program for surgical oncologists and specialized nurses on disparities in referral to breast cancer genetic testing

19. Reproductive decision-making in the context of hereditary cancer: the effects of an online decision aid on informed decision-making

20. Parent-of-origin-specific allelic associations among 106 genomic loci for age at menarche

21. A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46 450 cases and 42 461 controls from the breast cancer association consortium

22. Breast and ovarian cancer risks in a large series of clinically ascertained families with a high proportion of BRCA1 and BRCA2 Dutch founder mutations

24. Associations of Breast Cancer Risk Factors With Tumor Subtypes: A Pooled Analysis From the Breast Cancer Association Consortium Studies

25. Reproductive decision-making in the context of hereditary cancer: the effects of an online decision aid on informed decision-making

27. Online decision support for persons having a genetic predisposition to cancer and their partners during reproductive decision-making

28. Online decision support for persons having a genetic predisposition to cancer and their partners during reproductive decision-making

29. The development of an online decision aid to support persons having a genetic predisposition to cancer and their partners during reproductive decision-making: a usability and pilot study

30. The c. 5096G>A p.Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA consortium.

31. The BRCA1 c. 5096G>A p.Arg1699Gln (R1699Q) intermediate risk variant:breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA consortium

32. Online decision support for persons having a genetic predisposition to cancer and their partners during reproductive decision-making

33. The development of an online decision aid to support persons having a genetic predisposition to cancer and their partners during reproductive decision-making: a usability and pilot study

34. RAD51B in Familial Breast Cancer

35. The BRCA1 c. 5096G>A p.Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA consortium

36. FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium

37. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies

38. Efficacy of risk-reducing mastectomy (RRM) on overall survival (OS) in BRCA1/2-associated breast cancer (BC) patients.

39. The risk of primary and contralateral breast cancer after ovarian cancer inBRCA1/BRCA2mutation carriers

40. Mutations in SMAD3 cause a syndromic form of aortic aneurysms and dissections with early-onset osteoarthritis

41. Associations of Breast Cancer Risk Factors With Tumor Subtypes: A Pooled Analysis From the Breast Cancer Association Consortium Studies

42. The unfolding clinical spectrum of holoprosencephaly due to mutations in SHH, ZIC2, SIX3 and TGIF genes

43. Long-Term Morbidity and Health After Early Menopause Due to Oophorectomy in Women at Increased Risk of Ovarian Cancer: Protocol for a Nationwide Cross-Sectional Study With Prospective Follow-Up (HARMOny Study)

44. Variation in Mutation Spectrum Partly Explains Regional Differences in the Breast Cancer Risk of Female BRCA Mutation Carriers in the Netherlands.

45. The risk of primary and contralateral breast cancer after ovarian cancer in BRCA1/ BRCA2 mutation carriers.

46. RAD51B in Familial Breast Cancer

47. A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer

48. Refined histopathological predictors of BRCA1 and BRCA2mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia

49. Shared heritability and functional enrichment across six solid cancers

50. RAD51B in Familial Breast Cancer

Catalog

Books, media, physical & digital resources